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January 2010284 Abstractsmal. Patients with ABI  1.40 or (a history of) intermittent claudication
were excluded. Serial troponin-T measurements were performed routinely
before and after surgery. The main study endpoint was perioperative myo-
cardial damage, the composite of myocardial ischaemia and infarction.
Multivariate regression analyses, adjusted for conventional risk factors, eval-
uated the relation between asymptomatic low ABI and perioperative myo-
cardial damage.
Results: In total, 148 (23%) patients had asymptomatic low ABI (mean
0.73, standard deviation  0.13). Perioperative myocardial damage was
recorded in 107 (18%) patients. Multivariate regression analyses demon-
strated that asymptomatic low ABI was associated with an increased risk of
perioperative myocardial damage (odds ratio (OR): 2.4, 95% CI: 1.4–4.2)
Conclusions:This study demonstrated that asymptomatic low ABI has
a prognostic value to predict perioperative myocardial damage in vascular
surgery patients, incremental to risk factors imbedded in conventional
cardiac risk indices.
A Systematic Review of Implementation of Established Recommended
Secondary Prevention Measures in Patients with PAOD
Flu H.C., Tamsma J.T., Lindeman J.H.N., Hamming J.F., Lardenoye
J.H.P. Eur J Vasc Endovasc Surg 2010;39:70-86.
Objective: Since patients with peripheral arterial occlusive disease
(PAOD) are at high-risk for cardiovascular morbidity and mortality, preven-
tive measures aimed to reduce cardiovascular adverse events are advocated in
the current guidelines. We conducted a systematic review to assess the
implementation of secondary prevention (SP) measures in PAOD patients.
Methods: PubMed, Cochrane Library, EMBASE and Web of Science
databases were searched to perform a systematic review of the literature from
1999 till June 2008 on SP for PAOD patients. Assessment of study quality
was done following the Cochrane Library review system. The record out-
comes were antiplatelet agents, heart rate lowering agents, blood pressure
lowering agents, lipid lowering agents, glucose lowering agents, smoking
cessation and walking exercise.
Results: From a total of 2137 identified studies, 83 observational
studies met the inclusion criteria, of which 24 were included in the system-
atic review comprising 34 157 patients. These patients suffered from coro-
nary artery disease (n  3516, 41%), myocardial infraction (n  2647,
38%), angina pectoris (n  1790, 31%), congestive heart failure (n  2052,
14%), diabetes mellitus (n  10 690, 31%),hypertension (n  20 823, 73%)
and hyperlipidaemia (n  15 067, 64%). Contrary to what the guidelines
prescribe, antiplatelet agents, heart rate lowering agents, blood pressure
lowering agents and lipid lowering agents were prescribed in 63%, 34%, 46%
and 45% of the patients, respectively. Glucose lowering agents were pre-
scribed in 81% and smoking cessation in 39% of the patients.
Conclusion: The majority of patients suffering from PAOD do not
receive the entire approach of SP measures as suggested by the current
guidelines. To our knowledge, the cause of this undertreatment is multifac-
torial: patient, physician or health-care-related.
Endovenous Laser Ablation (980 nm) of the Small Saphenous Vein in
a Series of 147 Limbs with a 3-Year Follow-upReaders can access EJVES articles at http://intl.eAim: This study aims to demonstrate the treatment outcomes of
endovenous laser ablation (EVLA) of incompetent small saphenous veins
(SSVs) with a 980-nm diode laser.
Materials andmethods: Between 1 June 2003 and 30 June 2006, 128
patients (147 limbs) with varicose veins and reflux in the SSV on duplex
ultrasound (US) examination were treated with a 980-nm diode laser under
US guidance. EVLA was performed using pulsed mode with a power of
10 W. The pulse duration (1.5–3 s) was chosen to deliver a linear en-
dovenous energy density (LEED) depending on the SSV diameter measured
1.5 cm below the sapheno-popliteal junction (SPJ) with the patient stand-
ing. For SSV diameters between 2 and 4.5 mm, the LEED applied was
50 J cm1. The LEED was 70 J cm1 for 4.5–7 mm, 90 J cm1 for
7–10 mm. Patients were evaluated at 1-week, 1-month, 1-year, 2-year and
3-year follow-up.
Results: The initial technical success rate was 100% in 147 patients.
The SSV remained closed in 114 of 117 limbs (97%) after 1 year, all of 61
limbs after 2 years and all of 30 limbs after 3 years. For the three SSVs where
re-canalisation was observed, the diameter was greater than 9 mm. Major
complications have not been detected and, in particular, there was no deep
venous thrombosis (DVT). Ecchymoses were seen in 60% with a median
duration of 2 weeks. Temporary paraesthesia (mostly hypoaesthesia) was
observed in 40% of treated legs with a median duration of 2 weeks. The
maximum duration did not exceed 4 weeks. No skin discolouration, super-
ficial burn, thrombophlebitis or palpable induration was observed.
Conclusion: EVLA of the incompetent SSV with a 980-nm diode laser
appears to be an extremely safe technique. After successful treatment, there
is a very low rate of re-canalisation of the SSV. Obliteration of the SSV was
confirmed at 1-, 2- and 3-year follow-up; this study suggests that this
procedure will provide a lasting result.
Radiofrequency Ablation vs Conventional Surgery for Varicose Veins –
a Comparison of Treatment Costs in a Randomised Trial
Subramonia S., Lees T. Eur J Vasc Endovasc Surg 2010;39:104-11.
Objective: To compare the costs involved (from procedure to recov-
ery) following radiofrequency ablation and conventional surgery for lower
limb varicose veins in a selected population.
Design: Prospective randomised controlled trial.
Methods Patients with symptomatic great saphenous varicose veins
suitable for radiofrequency ablation were randomised to either RF ablation
or surgery (sapheno-femoral ligation and stripping). The hospital, general
practice and patient costs incurred until full recovery and the indirect cost to
society, due to sickness leave after surgery, were calculated to indicate mean
cost per patient under each category.
Results: Ninety three patients were randomised. Eighty eight patients
(47 – RF ablation, 41 – surgery) underwent the allocated intervention.
Ablation took longer to perform than surgery (mean 76.8 vs 47.0 min,
p  .001). Ablation was more expensive (mean hospital cost per patient
£1275.90 vs £559.13) but enabled patients to return to work 1 week earlier
than after surgery (mean 12.2 vs 19.8 days, p  0.006). Based on the
Annual Survey of Hours and Earnings (Office of National Statistics, UK) for
full time employees, the cost per working hour gained after ablation was
£6.94 (95% CI 6.26, 7.62).
Conclusion: The increased cost of radiofrequency ablation is partly
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Vasc Endovasc Surg 2010;39:99-103.
offset by a quicker return to work in the employed group
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